How Yervoy Coverage Affects Out-of-Pocket Costs
Yervoy (ipilimumab), a Bristol Myers Squibb immunotherapy for melanoma and other cancers, has high list prices—around $175,000 for a full treatment course. Insurance coverage determines most patient costs, with commercial plans, Medicare, or Medicaid covering 80-100% after deductibles. Without coverage, patients pay the full amount; with it, costs drop to copays of $0-$5,000 per cycle, depending on plan design.[1]
Does Medicare Cover Yervoy, and What Do Patients Pay?
Medicare Part B covers Yervoy infusions at 80% after the Part B deductible ($240 in 2024), leaving patients with 20% coinsurance—often $1,000-$3,000 monthly during treatment. Supplemental Medigap plans eliminate this coinsurance. Medicare Advantage plans vary, sometimes capping costs at $2,000-$5,000 annually.[2]
Commercial Insurance Coverage Rules for Yervoy
Private insurers like UnitedHealthcare or Blue Cross often cover Yervoy under medical benefits for FDA-approved uses, requiring prior authorization and proof of progression on prior therapies. Copays range from $100-$500 per infusion (tier 3-4 specialty drug), with out-of-pocket maxes at $2,000-$9,000 yearly. Step therapy (trying cheaper drugs first) or site-of-care restrictions (infusion center only) can delay access and raise costs.[1][3]
What Happens Without Insurance or with Gaps in Coverage?
Uninsured patients face full list price, though Bristol Myers offers copay assistance reducing it to $0 for eligible patients (income under 500% FPL). Coverage denials occur in 10-20% of cases due to off-label use or cost controls, forcing appeals or out-of-pocket payment. Patient assistance programs like BMS Access Support cover up to $25,000 annually for underinsured.[4]
How Prior Authorization and Utilization Management Impact Costs
Insurers mandate prior auth for Yervoy, reviewing biomarkers or scans, which delays treatment by 1-4 weeks. Failures lead to denials, shifting full costs to patients. Quantity limits (e.g., 4 infusions max) or fail-first requirements increase effective costs by prolonging illness.[3]
Yervoy Patient Assistance and Copay Cards
Bristol Myers' OneOncology or Access Support provides free drug for uninsured/low-income patients and copay cards slashing costs to $0-$5 per infusion for commercially insured (up to $15,000-$25,000/year). Eligibility requires U.S. residency and specific income limits; applications take 1-2 days.[4]
Factors Raising Yervoy Costs Despite Coverage
High deductibles ($1,500-$8,000 on average plans) hit early, plus 20% coinsurance on $30,000+ per infusion cycle. Site-of-care policies favor cheaper hospital outpatient departments over physician offices, adding $2,000-$5,000 per treatment. Combo therapy with Opdivo doubles exposure to these costs.[1][2]
[1]: DrugPatentWatch.com - Yervoy Pricing and Coverage
[2]: CMS.gov - Medicare Coverage for Immunotherapy
[3]: Institute for Clinical and Economic Review (ICER) - Yervoy Utilization Review
[4]: Bristol Myers Squibb Patient Assistance